Structural highlights from TCT: SCOPE I, COAPT and more
Healio was on-site at TCT 2019, which offered a number of late-breaking presentations on innovations in the treatment of structural heart disease. Below are some of the highlights.
SCOPE I: Acurate neo does not meet noninferiority for TAVR safety, efficacy vs. Sapien 3
SAN FRANCISCO — Transcatheter aortic valve replacement with the self-expanding Acurate neo device did not meet noninferiority compared with the balloon-expandable Sapien 3 device for the primary composite safety and efficacy endpoint at 30 days, according to results of the SCOPE I trial.
COAPT: MitraClip benefit maintained at 3 years in HF, mitral regurgitation
SAN FRANCISCO — The treatment effect of transcatheter mitral valve repair in patients with HF and moderate to severe or severe mitral regurgitation was even greater at 3 years than it was at 2 years, according to new data from the COAPT trial presented at TCT 2019.
Subclinical leaflet thrombosis not tied to serious clinical events: PARTNER 3 CT substudy
SAN FRANCISCO — In a CT substudy of the PARTNER 3 trial of low surgical risk patients who underwent transcatheter or surgical AVR, hypoattenuated leaflet thrombosis and reduced leaflet motion were not associated with death, MI and stroke, according to data presented at TCT 2019.
PARTNER 2A: TAVR remains similar to surgery for 5-year outcomes in intermediate-risk population
SAN FRANCISCO — At 5 years, TAVR with the Sapien XT device was similar to surgical AVR for death and disabling stroke in patients with severe aortic stenosis at intermediate surgical risk, according to new data from the PARTNER 2A trial.
Transcatheter tricuspid valve intervention confers benefit over medical management
SAN FRANCISCO — Among patients with tricuspid regurgitation, transcatheter tricuspid valve intervention plus medical management was associated with reduced risk for death and HF rehospitalization compared with medical management alone, according to data presented at TCT 2019.
Portico valve stacks up against commercially available TAVR valves
SAN FRANCISCO — In the Portico IDE study, 30-day safety and 1-year effectiveness of the Portico TAVR system was noninferior to contemporary commercially available valves in the U.S. for treatment of patients with severe aortic stenosis at high or extreme risk for surgery.
Operator experience plays key role in optimizing outcomes with transcatheter mitral valve repair
SAN FRANCISCO — Greater operator experience with transcatheter mitral valve repair using the MitraClip was associated with improvements in procedural success, time and complications, according to new research presented at TCT 2019.
Transseptal access confers lower mortality in mitral valve-in-valve repair
SAN FRANCISCO — Among patients who underwent transcatheter valve-in-valve repair of a failed surgical mitral valve, those who had transseptal access had lower mortality than those who had transapical access at 1 year, according to data presented at TCT 2019.
Novel percutaneous LV repair system shows promise in systolic HF
SAN FRANCISCO — Early clinical data suggest that an investigational percutaneous device designed to directly repair the left ventricle is feasible and safe in patients with HF and functional mitral regurgitation. Data on the first 31 patients enrolled in the CorCinch FMR early feasibility study who were treated with the AccuCinch ventricular repair system at U.S. centers through July were presented at TCT 2019.
Greater operator, hospital mitral valve surgery volume tied to reduced mortality, more repair
SAN FRANCISCO — Higher operator and hospital volume conferred better results for 30-day operative mortality, successful repair of primary mitral regurgitation and 1-year mortality, according to a presentation at TCT 2019.